CLLS Stock Overview
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cellectis S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.99 |
| 52 Week High | €3.77 |
| 52 Week Low | €0.96 |
| Beta | 3.12 |
| 1 Month Change | 21.54% |
| 3 Month Change | 3.46% |
| 1 Year Change | 71.84% |
| 3 Year Change | -81.05% |
| 5 Year Change | -82.61% |
| Change since IPO | -91.99% |
Recent News & Updates
Recent updates
FDA clears Cellectis' investigational new drug application for lymphoma treatment
Aug 01Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential
Jul 13Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside
Jun 22Cellectis outlines four new UCART preclinical programs; reveals .HEAL, a genome surgery platform
Jun 15Cellectis withdraws follow-on offering
Dec 16Cellectis initiates equity raise of $100M
Dec 14FDA lifts clinical hold on Cellectis' early-stage UCARTCS1 study in multiple myeloma
Nov 18Cellectis EPS misses by $0.10, misses on revenue
Nov 05Shareholder Returns
| CLLS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.3% | 3.2% | 1.7% |
| 1Y | 71.8% | 6.0% | 26.3% |
Return vs Industry: CLLS exceeded the US Biotechs industry which returned 7% over the past year.
Return vs Market: CLLS exceeded the US Market which returned 26.1% over the past year.
Price Volatility
| CLLS volatility | |
|---|---|
| CLLS Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: CLLS has not had significant price volatility in the past 3 months.
Volatility Over Time: CLLS's weekly volatility has decreased from 26% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 219 | Andre Choulika | www.cellectis.com |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Cellectis S.A. Fundamentals Summary
| CLLS fundamental statistics | |
|---|---|
| Market cap | US$206.35m |
| Earnings (TTM) | -US$109.45m |
| Revenue (TTM) | US$9.19m |
22.4x
P/S Ratio-1.9x
P/E RatioIs CLLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLLS income statement (TTM) | |
|---|---|
| Revenue | US$9.19m |
| Cost of Revenue | US$737.00k |
| Gross Profit | US$8.46m |
| Other Expenses | US$117.91m |
| Earnings | -US$109.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.53 |
| Gross Margin | 91.98% |
| Net Profit Margin | -1,190.59% |
| Debt/Equity Ratio | 38.0% |
How did CLLS perform over the long term?
See historical performance and comparison